Cargando…
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the second most common malignancy. Unfortunately, despite advances in multimodality therapeutics for the disease, the overall five-year survival rate among newly diagnosed lung cancer patients remains in the range region of 15%. In addition, although immune checkpoint inhibitors are i...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210654/ https://www.ncbi.nlm.nih.gov/pubmed/30257500 http://dx.doi.org/10.3390/jcm7100303 |